Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Spectral Medical Inc T.EDT

Alternate Symbol(s):  EDTXF

Spectral Medical Inc. is a Canada-based late-stage theragnostic company advancing therapeutic options for sepsis and septic shock. The Company develops and commercializes a treatment for septic shock utilizing its Endotoxin Activity Assay (EAA) diagnostic and the Toraymyxin therapeutic (PMX). PMX is a therapeutic hemoperfusion device that removes endotoxin, which can cause sepsis, from the bloodstream and is guided by the Company’s EAA. PMX is approved for therapeutic use in Japan and Europe and has been used safely and effectively on more than 340,000 patients to date. It has pioneered the development of biochemical markers for the clinical syndrome known as septic shock. It is continuing its legacy business of manufacturing and selling certain proprietary reagents. It develops, produces and markets recombinant proteins, antibodies and calibrators. These materials are sold for use in research and development, as well as in products manufactured by other diagnostic companies.


TSX:EDT - Post by User

Post by Stocktreeon Nov 08, 2023 1:59pm
200 Views
Post# 35724195

x sites, y patients, always underwhelming

x sites, y patients, always underwhelming
They announced they would have 25 sites up and running in september.
The are still at 19. They never achieve what they promised.
So how can a pumpcycle like MM predict 90 patients in short order, without being pummeled for his ridiculous pumping? Easy, there are about 12 active posters here, some being the same person.

Also, the halfway mark is just that. No reason at all to point at it other than for pumping reasons, or to earn your posting reward.

The number of patients enrolled is a farce, and defies logic.

2 patients a month? That means 17 sites enrolled 0 patients?

Either the study's parameters are so strict any trial success rate will have to be divided by a thousand, or sites only painfully agree to do one single test drive to get Spectral of their back, after which they ghost the company and proceed with their usual business and other trials.
<< Previous
Bullboard Posts
Next >>